TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

Benzinga Logo Benzinga By Vandana Singh
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

Top investors of STAAR Surgical, including Yunqi Capital and Broadwood Partners, have rejected Alcon's revised acquisition offer of $30.75 per share, citing a flawed sale process and insufficient valuation.

Insights
STAA   negative

Major shareholders believe the sale process is fundamentally flawed and does not maximize shareholder value